INVESTIGATION OF CYTOCHROM P450 2C19 GENETIC POLYMORPHISM AND ITS EFFECT ON THE THERAPY OUTCOME IN PATIENTS WITH GERDIN THE CRIMEAN POPULATION

Was investigated genetic polymorphism of cytochrome P450 2C19 and studied its effect on out- come of PPIs therapy in 136 patients of the Crimean population suffering from gastroesophageal reflux disease. Patients were divided into three groups: those with erosive esophagitis - 49, with non-erosive reflux disease - 60, with reflux hypersensitivity - 27. It was found that in that sample of patients of the Crimean population genetic polymorphism was introduced *1/*1 and *1/*2 genotypes. Carriage genotypes *1/*1 and *1/*2 are equally common among male and female. Patients with genotype *1/*2 are more likely to occur a complete response to PPIs therapy, than those who carry genotype *1/*1 (odds ratio 3.237). Patients with erosive esophagitis equally common carriers of both genotypes but patients with genotype *1/*1 more common show patrial respons to PPIs therapy (odds ratio 1,795). Among patients with NERd more often met favorable outcome of PPIs therapy, but the carrier of any of the genotypes was not identified as risk factor. Among patients with reflux hypersensitivity clinical respons to PPI therapy affected by CYP2C19 genotype condition: patients with genotype *1/*1 were more likely to develop treatment failures than those with *1/*2 genotype (odds ratio 2,786).

PPIs, GERd, cytochrome P 450, metabolism, treatment efficacy